Kolltan Pharmaceuticals Closes $10 Million Series B Related Financing
Company Has Raised a Total of $50 Million Since Inception

Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
Kolltan announced today the election of four external members to its Board of Directors and two new officers

Kolltan Pharmaceuticals Adds $5 Million to Close Series A Financing
Kolltan closes its Series A preferred stock financing at $40 million

Kolltan Founder, Board Member and Chairman of Scientific Advisory Board Publishes Article on Receptor Tyrosine Kinase Signaling

Kolltan Pharmaceuticals Opens Office and R&D Facility
in New Haven, Connecticut

Kolltan Pharmaceuticals Raises over $35 Million in Series A Financing
Proceeds to Fund Development Programs and Support Expansion of Senior Team

Michael Schmertzler Joins Kolltan Pharmaceuticals as CEO and Director
Yaron Hadari, Ph.D., Named Vice President of Research